• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Bridgebio Pharma Inc (NQ: BBIO )

    27.39 +0.72 (+2.70%)
    Streaming Delayed Price Updated: 2:17 PM EDT, Jul 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 476,003
    Open 26.23
    Bid (Size) 27.37 (2)
    Ask (Size) 27.40 (1)
    Prev. Close 26.67
    Today's Range 26.20 - 27.45
    52wk Range 21.62 - 44.32
    Shares Outstanding 160,500,999
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -32.29%
    -32.29%
    1 Month
    +19.09%
    +19.09%
    3 Month
    +9.25%
    +9.25%
    6 Month
    -28.00%
    -28.00%
    1 Year
    -17.60%
    -17.60%

    More News

    Read More
    ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday
    Via Benzinga
    Why BridgeBio Pharma Stock Is Trading Lower Tuesday
    Via Benzinga
    Masters In Trading - Saturday, June 22
    Via Talk Markets
    BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    The 3 Best Biotech Stocks to Buy in June 2024
    Via InvestorPlace
    BridgeBio Pharma Shares One Year Data From Dwarfism Candidate
    Via Benzinga
    BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results
    Via Investor's Business Daily
    BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    7 Biotech Stocks to Put on Your Breakthrough Radar
    Via InvestorPlace
    BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BBIO Stock Earnings: BridgeBio Pharma Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    From BridgeBio Pharma, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.